Floatz logo

m3814

Locally Advanced Pancreatic Adenocarcinoma

National Cancer Institute (NCI)Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Locally Advanced Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
SWOG Cancer Research Network
Phase 3B
Gdc-0449
OHSU Knight Cancer Institute
Phase 2B
Sargramostim
Barbara Ann Karmanos Cancer Institute
Phase 1/2B
Inno-206
OHSU Knight Cancer Institute
Phase 2B
Regorafenib
OHSU Knight Cancer Institute
Phase 2B

View all 50 →

Same molecule, other indications

m3814 is also rated in:

Advanced Solid TumorsDormant
CCC
Indicative ·
52 / 100
View asset →
Unresectable Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Locally Advanced Unresectable Gallbladder CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →